Analogic Corporation Signs Agreement with Sphere Medical to Develop Innovative Glucose Monitor for Critical Care Market.

PEABODY, Mass. -- Analogic Corporation (NASDAQ: ALOG) today announced that the Company has entered into an agreement with Sphere Medical of Cambridge, UK, to develop and manufacture instruments for the monitoring of key blood parameters, such as glucose, blood gases, and electrolytes, in critical care patients.

Hyperglycemia, or high blood-sugar levels, is a common condition in critically ill patients that can significantly increase the possibility of death. Close control of glucose in these patients, according to the landmark Van den Bergh study, can result in improved patient outcomes and reduced patient mortality.

Stuart Hendry, Sphere Medical's CEO, said, "Our proprietary Proxima system will initially be applied to the monitoring of glucose, in which there is a strong current interest. However, critical care patients need frequent testing of many blood parameters, and our capability of simultaneously measuring other key blood components, such as blood gases and electrolytes, sets us apart in the field. Our focus at Sphere is on the continual improvement of critical care. By teaming with Analogic, a recognized leader in signal processing and the development of advanced medical instrumentation, we will bring a new generation of products to the critical care arena, which will give clinicians better control over the therapy delivered with expected improvements in patient outcomes."

"Analogic has a history of developing world-class patient monitors for leading Original Equipment Manufacturers (OEMs)," said Dan Webster, General Manager, Analogic Life Care Systems Division. "We look forward to working with Sphere Medical to raise the standard of patient monitoring in critical care that will both improve and save lives."

Analogic Corporation is a leading designer and manufacturer of advanced health and security systems and subsystems sold primarily to Original Equipment Manufacturers (OEMs). The Company is recognized worldwide for advancing the state of the art in Computed Tomography (CT), Digital Radiography (DR), Ultrasound, Magnetic Resonance Imaging (MRI), and Patient Monitoring.

Sphere Medical Limited is developing highly innovative monitoring products to provide clinical and economic benefits in the critical care environment, based on the company's proprietary technology. The products allow minimally invasive, real time measurement of clinical chemistry parameters and therapeutic drug concentrations, giving healthcare professionals the information they require to more effectively manage therapy and optimise patient outcomes. Sphere Medical is a private company, founded in 2002 and based in Cambridge, UK. For further information please see www.spheremedical.com.